Internal Reference: 2025-096

Market Need 

Clostridium perfringens is a fast‑growing, toxin‑producing anaerobic bacterium responsible for a range of severe diseases in animals and humans. In poultry, it is the primary agent of necrotic enteritis (NE)—a costly intestinal disease that leads to gut necrosis, high mortality, poor weight gain, and billions in global economic losses annually. The pathology is driven largely by secreted toxins, which orchestrate toxin expression during infection. When the gut environment becomes compromised—for example during coccidial infection or diet changes—the bacterium transitions from a harmless commensal to a potent pathogen, amplifying toxin production and causing rapid disease progression.

The Solution

This technology introduces a new class of precision antisense antimicrobials designed to neutralize Clostridium perfringens virulence without disrupting healthy microbiota. The invention uses peptide nucleic acids (PNAs) engineered to bind specifically to mRNAs encoding three key virulence factors. By binding near the translation start site, these PNAs block protein synthesis through a steric‑hindrance mechanism, reducing toxin production while allowing normal bacterial growth to continue—an essential feature for microbiome‑safe therapeutics.

To enhance delivery into bacterial cells, the antisense oligomers are conjugated to cell‑penetrating peptides (CPPs), forming CPP–PNA constructs with highly efficient intracellular uptake. Laboratory studies demonstrate two complementary modes of action: PNAs targeting essential genes exert potent bactericidal effects, while PNAs targeting virulence‑associated genes significantly suppress toxin levels, hemolytic activity, and cytotoxicity toward chicken liver cells—without inhibiting bacterial proliferation.

The Benefits

• Targets virulence, not bacterial survival – preserving the microbiome
• Reduces selective pressure for antimicrobial resistance
• Precise, programmable control of bacterial pathogenicity

Additional Information

• Researcher: Xin Zhao
• Patents: US Provisional (Filed)